ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

DERM Journey Medical Corporation

5.46
-0.05 (-0.91%)
20 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Journey Medical Corporation NASDAQ:DERM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -0.91% 5.46 4.74 5.75 5.64 5.32 5.49 30,840 05:00:06

Dermira to Present at Evercore ISI HealthCONx Conference

19/11/2018 1:00pm

GlobeNewswire Inc.


Journey Medical (NASDAQ:DERM)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Journey Medical Charts.

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the Evercore ISI HealthCONx Conference.

  • Location: Boston, MA
  • Presentation date: Tuesday November 27, 2018
  • Presentation time: 2:00 p.m. ET

A live audio webcast and archive of the presentation will be available at http://investor.dermira.com.

About Dermira

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology programs. The company’s approved treatment, QBREXZA™ (glycopyrronium) cloth, is indicated for pediatric and adult patients (ages nine and older) with primary axillary hyperhidrosis (excessive underarm sweating). Dermira is also evaluating lebrikizumab in a Phase 2b clinical trial for the treatment of moderate-to-severe atopic dermatitis (a severe form of eczema) and has early-stage research programs in other areas of dermatology. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow Dermira on Twitter, LinkedIn and Instagram.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc-), corporate Instagram account (https://www.instagram.com/dermira_inc/) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page, Instagram and Twitter accounts in addition to following its SEC filings, news releases, public conference calls and webcasts.

Contacts:

Media:

Erica JeffersonVice President, Corporate Communications650-421-7216erica.jefferson@dermira.com

Investors:

Ian Clements, Ph.D.Vice President, Investor Relations650-422-7753investor@dermira.com

1 Year Journey Medical Chart

1 Year Journey Medical Chart

1 Month Journey Medical Chart

1 Month Journey Medical Chart

Your Recent History

Delayed Upgrade Clock